Laboratory Tests for Depression and Other Psychiatric Disorders (CPB 0306, reviewed 2026-06-08)
Summary
Aetna considers the dexamethasone suppression test medically necessary only when a psychiatrist requests it to differentiate psychotic depression from schizophrenia. The policy considers the test experimental, investigational, or unproven for diagnosing major depressive disorder, selecting medications for major depressive illness, and diagnosing or managing borderline personality disorder or post-traumatic stress syndrome. It also considers MindX blood tests, microRNA measurement, neutrophil-to-lymphocyte, monocyte-to-lymphocyte and platelet-to-lymphocyte ratios for diagnosing depression, and the TruD MDS bipolar, major depressive disorder and schizophrenia tests experimental, investigational, or unproven.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.